On August 15th, 2025, the FDA granted an accelerated and conditional approval of the subcutaneous glucagon‐like peptide (GLP‐1) receptor agonist (GLP1‐RA) semaglutide 2.4 mg/week for the treatment of MASH with moderate to advanced fibrosis (Stage F2‐F3) [7]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.